What you should know:
– PostEra, a biotechnology company specializing in machine learning for the discovery of preclinical drugs, today announced $ 24 million in capital funding to accelerate medical chemistry and provide new care to patients.
– PostEra will use the proceeds to advance a number of associated drug discovery programs, initiate its own internal drug discovery, and further develop its medicinal chemistry platform. True to its collaborative ethos, the company also announced today its multi-objective strategic partnership with Pfizer to establish an AI lab.
– In addition, PostEra announced the expansion of the company’s existing strategic partnership with Pfizer.
$ 260 million strategic AI lab collaboration with Pfizer
The expanded multi-objective research program will establish an AI lab where PostEra and Pfizer will jointly advance various drug discovery programs with an initial focus on COVID-19 oncology and antiviral therapy. The AI Lab will leverage new machine learning for medical chemistry based on Pfizer data and PostEra’s pioneering innovations in generative chemistry and synthesis-conscious design.
PostEra will receive an advance payment of $ 13 million and is eligible to receive additional milestone payments totaling $ 248 million if all milestones are met, in addition to tiered copyright on any product. approved to emerge from the collaboration.
He TO THE Lab will closely integrate drug discovery with technology development to ensure a continuous feedback loop that perfects both the process and the platform’s predictions. AI Lab’s vision is to combine Pfizer’s experience and data with PostEra technology to advance these drug discovery programs, while producing a state-of-the-art integrated platform that will be deployed in internal efforts. Pfizer Preclinical Drug Discovery